[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100462763":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":57,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Minneapolis Heart Institute Foundation","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","ACTIVE_COMPARATOR","Treatment group will receive SGLT2 inhibitor in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.",[13],"Drug: SGLT-2 inhibitors",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","Placebo Group will receive placebo in addition to standard heart attack medications for the duration of hospitalization and 6-month duration of the study.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","SGLT-2 inhibitors","SGLT2 inhibitor once daily for six months",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Placebo once daily for six months",[15],[32],{"name":33,"affiliation":5,"role":34},"Jay Traverse, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Sarah Schwager, RN","CONTACT","612-863-3833","sarah.schwager@allina.com",[42],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Minneapolis","Minnesota","55407","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-93.26384,44.97997,{"lat":53,"lon":52},[56],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"type":58,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100462763","phase-2-sodium-glucose-co-transporter-2-sglt2-and-stemi-100462763",false,"NCT05305911","Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI","Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).","Inclusion Criteria:\n\n* Patients with their first STEMI (\\>18 years) who underwent successful primary PCI and able to give informed consent\n* At least mild LV dysfunction (LVEF \\\u003C 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI\n* Infarct size that is \\> 10% of LV mass\n* The presence of MVO that is \\> 10% of infarct size\n\nExclusion Criteria:\n\n* Contraindication to cardiac MRI\n* Life expectancy \\\u003C 1 year\n* Previous CABG or Valve Surgery\n* Previous STEMI\n* Pregnant or planning to become pregnant or lactating women\n* Cardiogenic shock (not resolved)\n* Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)\n* GFR\\\u003C30 ml\u002Fmin\u002F1.73m2 or end-stage renal disease on dialysis\n* Type 1 diabetes mellitus or history of diabetic ketoacidosis\n* Type I or II diabetes with insulin use\n* Prior intolerance of SGLT2 inhibitors\n* Current use of SGLT2 inhibitors (randomized patients only)\n* Contraindications to gadolinium","ALL","18 Years","75 Years",{"count":70,"type":71},81,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.",[77,78],"Heart Attack","Enlarged Heart",[80,81],"Dapagliflozin","Sodium Glucose Co-Transporter 2","2024-10-03",{"date":84,"type":85},"2024-10-08","ACTUAL",{"date":87,"type":85},"2022-08-03",{"date":89,"type":71},"2028-12",{"name":5,"class":6},1]